Press Releases

Our latest news and press releases

Cellectis’ Annual Shareholders General Meeting to be Held on June 27, 2023

Read more

Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023

Read more

Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors

Read more

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

Read more

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023

Read more

Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Read more

Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023

Read more

Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofi’s Alemtuzumab

Read more

Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting

Read more

Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22

Read more